The transmissible spongiform encephalopathies (TSEs), or prion diseases, are a group of fatal neurodegenerative disorders including scrapie in sheep,[
Chinese Physics B, Volume. 29, Issue 10, (2020)
Structural and dynamical mechanisms of a naturally occurring variant of the human prion protein in preventing prion conversion
Prion diseases are associated with the misfolding of the normal helical cellular form of prion protein (PrPC) into the β-sheet-rich scrapie form (PrPSc) and the subsequent aggregation of PrPSc into amyloid fibrils. Recent studies demonstrated that a naturally occurring variant V127 of human PrPC is intrinsically resistant to prion conversion and aggregation, and can completely prevent prion diseases. However, the underlying molecular mechanism remains elusive. Herein we perform multiple microsecond molecular dynamics simulations on both wildtype (WT) and V127 variant of human PrPC to understand at atomic level the protective effect of V127 variant. Our simulations show that G127V mutation not only increases the rigidity of the S2–H2 loop between strand-2 (S2) and helix-2 (H2), but also allosterically enhances the stability of the H2 C-terminal region. Interestingly, previous studies reported that animals with rigid S2–H2 loop usually do not develop prion diseases, and the increase in H2 C-terminal stability can prevent misfolding and oligomerization of prion protein. The allosteric paths from G/V127 to H2 C-terminal region are identified using dynamical network analyses. Moreover, community network analyses illustrate that G127V mutation enhances the global correlations and intra-molecular interactions of PrP, thus stabilizing the overall PrPC structure and inhibiting its conversion into PrPSc. This study provides mechanistic understanding of human V127 variant in preventing prion conversion which may be helpful for the rational design of potent anti-prion compounds.
1. Introduction
The transmissible spongiform encephalopathies (TSEs), or prion diseases, are a group of fatal neurodegenerative disorders including scrapie in sheep,[
The key hallmark underlying the pathological misfolding and aggregation of PrPs is the conformational transition from a helix-rich conformer (PrPC, in which C stands for cellular) to a sheet-rich pathogenic (or scrapie-like) conformation (PrPSc).[
Figure 1.Stability and rigidity of WT PrP and its V127 variant. (a) A snapshot of the human PrP structure. (b)–(c) PDF of RMSD values in four consecutive time windows of (b) WT systems and (c) G127V systems. (d) RMSF of each residue on WT and G127V averaging over the three individual simulations for each system. The error bars are calculated by computing independent values from each individual simulation and taking the maximums and minimums of those values. The two regions where RMSF of G127V is remarkably lower than that of WT are labeled (1) and (2).
About 10% to 15% of human prion diseases are caused by mutations of the PrP.[
Molecular dynamics (MD) simulations have been widely used to investigate the structural and dynamical properties of proteins.[
2. Results and discussion
2.1. G127V mutation increases the S2–H2 loop rigidity and H2 C-terminal stability
We have performed three individual 2-μs-long simulations for both the globular domain of WT PrP (comprising residues 125–228) and its V127 variant. The initial structure of WT PrP is taken from a solution NMR structure,[
We further investigate the influence of G127V mutation on the structural rigidity of PrP by calculating the root mean square fluctuation (RMSF) of both WT and G127V systems. As shown in Fig. 1(d), the RMSF values of almost all residues in G127V are lower than those of WT (except for a few residues on the S1–H1 loop). In the WT system, the residues in the S2–H2 loop (region 1, residues 164–174) and the residues in the C-terminal of H2 and those in H2–H3 loop (region 2, residues 192–197) have much higher RMSF values than other non-terminal residues, indicating their higher flexibilities than the other residues. The high flexibilities of these two regions are consistent with previous atomistic and coarse-grained simulation studies on WT PrP.[
The misfolding of PrP monomer and the consequent oligomerization/fibrilization are closely related to the prion disease pathology.[
The solution-state NMR structures of bank vole, elk, and horse PrPs have been reported (PDBID: 2K56, 1XYW, 2KU4).[
Figure 2.Conformational characteristics of the S2–H2 loop. (a) Snapshots of the S2–H2 loop (residue 165–174) in three prion-resistant PrPs. The red and blue dashed boxes correspond to the two structural characteristics: a helix-like structure and a turn-like loop. (b) The Ramachandran plot of residue D167 in bank vole, elk, and horse PrPs. (c)–(f) Snapshots of the representative conformations of (c) the top four S2–H2 loop clusters in WT-1 MD run and of (c)–(e) the top one cluster in each G127V MD run. (g)–(h) PMF of D167 plotted as a function of the (
To show whether the S2–H2 loop in V127 variant has a conformation similar to that in bank vole, elk, and horse PrPs, we perform cluster analysis on their conformations in the last 1 μs of the trajectories using a single-linkage algorithm[
2.2. G127V mutation enhances local hydrophobic, H-bonding, and salt-bridge interactions in the vicinity of S2–H2 loop
Although residues in the S2–H2 loop (residues 164–174) are distant from the mutation site (V127) in sequence, they are spatially close to each other (see Fig. 1(a)). We perform interaction analysis to understand how the G127V mutation improves the rigidity of the S2–H2 loop. Valine has a bulky hydrophobic side chain while glycine has no side chain, so we suspect that the hydrophobic interactions may play an important role. By calculating the contact probability between G/V127 and all residues in the S2–H2 loop, we find that the hydrophobic residue P165 has the highest contact probability with V127 (
Figure 3.Influence of G127V mutation on the interactions in the vicinity of residue 127 and S2–H2 loop. (a), (c), (f) Time evolution of (a) contact number between G/V127 and P165, (c) number of H-bonds between residues 125–129 and residues 162–169, and (f) centroid distance between residue R164 and D178 charged sidechain groups, in WT-1 (blue line) and in G127V-1 (red line). (b), (d), (g) Statistical analysis using a combined trajectory of the last 1.0 μs in the three simulations of WT and G127V systems. (e) Time evolution of H-bond numbers between residues 125–129 and residues 162–169. Only residue pairs forming H-bonds in more than 1/4 of simulation time are shown. (h)–(i) Representative snapshots of the N-terminal region and the S2–H2 loop region of (h) WT system, and (i) G127V system. (j)–(k) Snapshots of the G127V showing (j) the E168-involved H-bonds, and (k) the R164-D178 salt bridge.
The enhanced V127–P165 hydrophobic interaction may facilitate other residues in PrP fragment 125LGVYM129 to interact with the S2–H2 loop (162YYRPMDEY169). We calculate the H-bond number between them. As shown in Fig. 3(c), the H-bond number in G127V-1 run increases with simulation time and reaches ∼ 5, while that in WT-1 run fluctuates around 3. Similar results are observed in WT-2/3 and G127V-2/3 systems (
It has been reported that the R164–D178 salt bridge plays an important role on the structural stability of PrP.[
Taken together, the G127V mutation enhances the V127–P165 hydrophobic interaction, the E165-L125/G126/V127 H-bonds, and the R164–D178 salt bridge. These interactions collectively rigidify the S2–H2 loop of PrP.
2.3. Dynamical network analysis reveals the allosteric paths from the mutation site G/V127 to the C-terminal of H2
As mentioned above, G127V mutation also enhances the stability of H2 C-terminal region (residues 192–197). This region is far from the mutation site (G/V127) both in sequence and in space, suggesting that G127V improves the H2 C-terminal stability through an allosteric effect. The optimal dynamical path analysis method has been demonstrated as a useful tool for identifying allosteric paths in various proteins.[
In WT PrP system, we identify two shortest network paths from G127 to G195 (path length = 317) as well as 15 paths with slightly longer path lengths (between 317 and 327). As shown in
Figure 4.Allosteric paths from the mutation site (G/V127) to the C-terminal of H2 in WT and G127V systems. (a), (d) Optimal path from residue G/V127 to G195 in (a) WT PrP and (d) G127V. (b), (e) The correlation values of residue pairs forming the edges along (b) the G127–G195, and (e) the V127–G195 optimal paths. (c), (f) Percentage of optimal path length increase upon removal of each node of (c) WT and (f) G127V optimal paths.
2.4. G127V mutation strengthens the global correlation of the PrP
We further investigate the effect of G127V mutation on the global correlation of PrP by calculating the correlation values between each two residues. As shown in Fig. 5(a), the WT PrP correlation map contains three diagonal positively-correlated regions corresponding to the inter-residue interactions in the three helices (red circles), an off-diagonal region corresponding to the anti-parallel H2–H3 interaction (blue circle), and two regions corresponding to H2/H3–S2 interactions (green circles). The G127V correlation map has a similar pattern to that of WT, but the correlation values of the six positively-correlated regions are mostly higher than those of WT (Fig. 5(b)). In addition, more positively-correlated regions are observed in the correlation map of G127V system. These results demonstrate that the inter-residue correlations in PrP significantly increase after G127V mutation.
Figure 5.Correlation and community network analysis of WT and V127 variant. (a)–(b) Inter-residue correlation matrices of (a) WT and (b) G127V systems. (c)–(d) Community networks of (c) WT and (d) G127V systems. Left panels: snapshots of the proteins colored by communities. Right panels: schematic diagrams of the community networks. Each circle represents a single community. The size of the circle and the width of the edges correspond respectively to the size of the community and the connectivity strength between two communities.
Community network method has become a useful strategy for analyzing global correlations for biomolecules.[
3. Conclusions
We have performed six 2-μs-long MD simulations on the globular domain of WT human PrP and its V127 variant to investigate the effect of G127V mutation on the structural and dynamical properties of monomeric human PrP, with the aim of understanding the mechanism of G127V’s disease-prevention. RMSD and RMSF analyses show that G127V mutation increases the structural stability and rigidity of PrP. Especially, (1) the rigidity of the S2–H2 loop is greatly increased, and (2) the stability of the C-terminal of H2 is enhanced. The increased rigidity and stability of these two regions may inhibit the prion conversion of PrPC into toxic PrPSc, thus prevents prion diseases. Our speculation is supported by the fact that prions are poorly transmissible to animals with rigid S2–H2 loop and recent findings showing that stabilization of H2 of prion protein prevents its misfolding and oligomerization. Interaction analysis shows that the increased rigidity of the S2–H2 loop results from the enhanced V127–P165 hydrophobic interaction, E165-L125/G126/V127 H-bonds, and R164–D178 salt bridge. The mutation-induced stabilization of the R164–D178 salt-bridge enables the formation of a new allosteric path from the mutation site to the H2 C-terminal with a much shorter path length than the optimal path in WT. The WT optimal path still exists in G127V and becomes the suboptimal path. The new optimal path and the shortened suboptimal path lead to an enhanced stability of the H2 C-terminal. At last, community network analysis shows that the global correlations and interactions in PrP are strengthened by the G127V mutation. Our findings provide structural and dynamical basis for understanding the role of human V127 variant in preventing prion conversion and propagation, which may be helpful for the rational design of potent anti-prion therapies.
4. Material and methods
4.1. MD simulations
The initial structure of WT PrP globular domain was taken from a solution NMR structure comprising residues 125–228 (PDBID: 1HJM).[
4.2. Trajectory analysis
Trajectory analysis was performed using our in-house-developed codes and the facilities implemented in the GROMACS-5.1.2 software package.[
4.3. Generation of weighted dynamical networks
Dynamical networks of WT and G127V were generated using our in-house-developed codes. Each Cα atom was selected as a representative node for the corresponding residue. Edges were added between two nodes if the corresponding residues are in contact during a majority of the simulation time (> 70%). Nearest neighbors in sequence are not considered to be in contact as they lead to a number of trivial allosteric paths in the weighted network. The weight of each edge was defined as –log | Cij|, where Cij stands for the dynamic cross correlation of two nodes (i and j), so that the network distance between two nodes connected by an edge decreases as the correlation of the two corresponding residues increases.
4.4. Optimal and suboptimal allosteric path analysis
On the basis of the dynamical networks, the allosteric signal transmission from the mutation site (G/V127) to the C-terminal of H2 (residues 192–197) was analyzed by calculating the allosteric paths between residue G/V127 and residue G195. The length of a path Dij between distant residues i and j was defined as the sum of the edge weights between the consecutive nodes k, l along the path: Dij = Σk,lwkl. The path between residues i and j with the shortest distance
4.5. Community network analysis
We calculated the shortest network path between each residue pair (i, j, for i ≠ j). The betweenness of each edge was then defined as the number of shortest paths that cross that edge. The optimal community distribution was calculated using the Girvan–Newman algorithm,[
[1] J R GREIG. J. Comp. Pathol., 60, 263(1950).
[2] N Hunter. Br. Med. Bull., 66, 171(2003).
[3] E S Williams, S Young. J. Wildl. Dis., 16, 89(1980).
[4] M A Chatigny, S B Prusiner. Rev. Infect. Dis., 2, 713(1980).
[5] R G Will, J W Ironside, M Zeidler, S N Cousens, K Estibeiro, A Alperovitch, S Poser, M Pocchiari, A Hofmar, P G Smith. Lancet, 347, 921(1996).
[6] J Collinge. Lancet, 354, 317(1999).
[7] E Lugaresi, R Medori, P Montagna, A Baruzzi, P Cortelli, A Lugaresi, P Tinuper, M Zucconi, P Gambetti. N. Engl. J. Med., 315, 997(1986).
[8] R Medori, H-J Tritschler, A LeBlanc, F Villare, V Manetto, H Y Chen, R Xue, S Leal, P Montagna, P Cortelli, P Tinuper, P Avoni, M Mochi, A Baruzzi, J J Hauw, J Ott, E Lugaresi, L Autilio-Gambetti, P Gambetti. N. Engl. J. Med., 326, 444(1992).
[9] D C Gajdusek. Trans. R. Soc. Trop. Med. Hyg., 57, 151(1963).
[10] J D Matthews, R Glasse, S Lindenbaum. Lancet, 2, 449(1968).
[11] J S Griffith. Nature, 215, 1043(1967).
[12] C F Farquhar, R A Somerville, M E Bruce. Nature, 391, 345(1998).
[13] W Q Zou, P Gambetti. Cell, 121, 155(2005).
[14] C Soto. Trends Biochem. Sci., 36, 151(2011).
[15] S B Prusiner. Science, 216, 136(1982).
[16] M F Tuite, T R Serio. Nat. Rev. Mol. Cell Biol., 11, 823(2010).
[17] B Frost, M I Diamond. Nat. Rev. Neurosci., 11, 155(2010).
[18] J M Nussbaum, S Schilling, H Cynis, A Silva, E Swanson, T Wangsanut, K Tayler, B Wiltgen, A Hatami, R Rönicke, K Reymann, B Hutter-Paier, A Alexandru, W Jagla, S Graubner, C G Glabe, H U Demuth, G S Bloom. Nature, 485, 651(2012).
[19] A Chaari, M Ladjimi. Int. J. Biol. Macromol., 136, 57(2019).
[20] M Masuda-Suzukake, T Nonaka, M Hosokawa, T Oikawa, T Arai, H Akiyama, D M A Mann, M Hasegawa. Brain, 136, 1128(2013).
[21] Y Chu, J H Kordower. Curr. Neurol. Neurosci. Rep., 15, 1(2015).
[22] M Polymenidou, D W Cleveland. Cell, 147, 498(2011).
[23] A Prasad, V Bharathi, V Sivalingam, A Girdhar, B K Patel. Front. Mol. Neurosci., 12, 25(2019).
[24] K Abid, C Soto. Cell. Mol. Life Sci., 63, 2342(2006).
[25] D Riesner. Br. Med. Bull., 66, 21(2003).
[26] L Kupfer, W Hinrichs, M Groschup. Curr. Mol. Med., 9, 826(2009).
[27] L Calzolai, R Zahn. J. Biol. Chem., 278(2003).
[28] R Zahn, A Liu, T Lührs, R Riek, C Von Schroetter, F L Garcia, M Billeter, L Calzolai, G Wider, K Wüthrich. Proc. Natl. Acad. Sci. USA, 97, 145(2000).
[29] L Calzolai, D A Lysek, P Güntert, C Von Schroetter, R Riek, R Zahn, K Wüthrich. Proc. Natl. Acad. Sci. USA, 97, 8340(2000).
[30] K J Knaus, M Morillas, W Swietnicki, M Malone, W K Surewicz, V C Yee. Nat. Struct. Biol., 8, 770(2001).
[31] L Westergard, H M Christensen, D A Harris. Biochim. Biophys. Acta. (BBA)-Mol. Basis Dis., 1772, 629(2007).
[32] L Provenzano, Y Ryan, D A Hilton, J Lyons-Rimmer, F Dave, E A Maze, C L Adams, R Rigby-Jones, S Ammoun, C O Hanemann. Oncogene, 36, 6132(2017).
[33] L Linsenmeier, H C Altmeppen, S Wetzel, B Mohammadi, P Saftig, M Glatzel. Biochim. Biophys. Acta-Mol. Cel. Res., 1864, 2128(2017).
[34] G R Wu, T C Mu, Z X Gao, J Wang, M S Sy, C Y Li. J. Biol. Chem., 292(2017).
[35] R Linden. Front. Mol. Neurosci., 10, 77(2017).
[36] T M Franzmann, M Jahnel, A Pozniakovsky, J Mahamid, A S Holehouse, E Nüske, D Richter, W Baumeister, S W Grill, R V Pappu, A A Hyman, S Alberti. Science, 359, 6371(2018).
[37] K M Pan, M Baldwin, J Nguyen, M Gasset, A Serban, D Groth, I Mehlhorn, Z Huang, R J Fletterick, F E Cohen, S B Prusiner. Proc. Natl. Acad. Sci. USA, 90(1993).
[38] R Diaz-Espinoza, C Soto. Nat. Struct. Mol. Biol., 19, 370(2012).
[39] H Wille, J Requena. Pathogens, 7, 20(2018).
[40] W-Q Zou, X Zhou, J Yuan, X Xiao. Prion, 5, 172(2011).
[41] J Ma, S Lindquist. Science, 298, 1785(2002).
[42] G S Jackson. Science, 283, 1935(1999).
[43] H Wang, D D Rhoads, B S Appleby. Curr. Opin. Infect. Dis., 32, 272(2019).
[44] R B Petersen, P Parchi, S L Richardson, C B Urig, P Gambetti. J. Biol. Chem., 271(1996).
[45] J J Zarranz, A Digon, B Atarés, A B Rodríguez-Martinez, A Arce, N Carrera, I Fernández-Manchola, M Fernández-Martínez, C Fernández-Maiztegui, I Forcadas, L Galdos, J C Gómez-Esteban, A Ibáñez, E Lezcano, A De López Munain, J F Martí-Massó, M M Mendibe, M Urtasun, J M Uterga, N Saracibar, F Velasco, M M De Pancorbo. J. Neurol. Neurosurg. Psychiatry, 76, 1491(2005).
[46] J Woulfe, A Kertesz, I Frohn, S Bauer, P S George-Hyslop, C Bergeron. Acta Neuropathol., 110, 317(2005).
[47] M C Tartaglia, J N Thai, T See, A Kuo, R Harbaugh, B Raudabaugh, I Cali, M Sattavat, H Sanchez, S J DeArmond, M D Geschwind. J. Neuropathol. Exp. Neurol., 69, 1220(2010).
[48] M S Palmer, A J Dryden, J T Hughes, J Collinge. Nature, 352, 340(1991).
[49] S Shibuya, J Higuchi, R W Shin, J Tateishi, T Kitamoto. Ann. Neurol., 43, 826(1998).
[50] M Soldevila, F Calafell, A M Andrés, J Yagüe, A Helgason, K Stefánsson, J Bertranpetit. Hum. Mutat., 22, 104(2003).
[51] M Takayanagi, K Suzuki, T Nakamura, K Hirata, K Satoh, T Kitamoto. Rinsho Shinkeigaku, 58, 682(2018).
[52] S Mead, J Whitfield, M Poulter, P Shah, J Uphill, T Campbell, H Al-Dujaily, H Hummerich, J Beck, C A Mein, C Verzilli, J Whittaker, M P Alpers, J Collinge. N. Engl. J. Med., 361, 2056(2009).
[53] E A Asante, M Smidak, A Grimshaw, R Houghton, A Tomlinson, A Jeelani, T Jakubcova, S Hamdan, A Richard-Londt, J M Linehan, S Brandner, M Alpers, J Whitfield, S Mead, J D F Wadsworth, J Collinge. Nature, 522, 478(2015).
[54] A T Sabareesan, J B Udgaonkar. Biochemistry, 56, 5931(2017).
[55] A C Pan, D Jacobson, K Yatsenko, D Sritharan, T M Weinreich, D E Shaw. Proc. Natl. Acad. Sci. USA, 116, 4244(2019).
[56] M Bermudez, J Mortier, C Rakers, D Sydow, G Wolber. Drug Discov. Today, 21, 1799(2016).
[57] N Plattner, S Doerr, G De Fabritiis, F Noé. Nat. Chem., 9, 1005(2017).
[58] S Zhou, D Shi, X Liu, H Liu, X Yao. Sci. Rep., 6(2016).
[59] Z Zheng, M Zhang, Y Wang, R Ma, C Guo, L Feng, J Wu, H Yao, D Lin. Sci. Rep., 8, 1(2018).
[60] E El-Bastawissy, M H Knaggs, I H Gilbert. J. Mol. Graph. Model., 20, 145(2001).
[61] M Sekijima, C Motono, S Yamasaki, K Kaneko, Y Akiyama. Biophys. J., 85, 1176(2003).
[62] L A Mandujano-Rosas, D Osorio-González, P G Reyes-Romero, J Mulia-Rodríguez. Open J. Biophys., 04, 169(2014).
[63] G Borgohain, N Dan, S Paul. Biophys. Chem., 213, 32(2016).
[64] Y Gao, T Zhu, C Zhang, J Z H Zhang, Y Mei. Chem. Phys. Lett., 706, 594(2018).
[65] A Barducci, R Chelli, P Procacci, V Schettino, F L Gervasio, M Parrinello. J. Am. Chem. Soc., 128, 2705(2006).
[66] E Caldarulo, A Barducci, K Wüthrich, M Parrinello. Proc. Natl. Acad. Sci. USA, 114, 9617(2017).
[67] D Huang, A Caflisch. J. Am. Chem. Soc., 137, 2948(2015).
[68] M Avbelj, I Hafner-Bratkovič, R Jerala. Biochem. Biophys. Res. Commun., 413, 521(2011).
[69] T D Kurt, P Aguilar-Calvo, L Jiang, J A Rodriguez, N Alderson, D S Eisenberg, C J Sigurdson. J. Biol. Chem., 292(2017).
[70] C J Sigurdson, K P R Nilsson, S Hornemann, G Manco, N Fernández-Borges, P Schwarz, J Castilla, K Wüthrich, A Aguzzi. J. Clin. Invest., 120, 2590(2010).
[71] B Christen, D R Pérez, S Hornemann, K Wüthrich. J. Mol. Biol., 383, 306(2008).
[72] A D Gossert, S Bonjour, D A Lysek, F Fiorito, K Wüthrich. Proc. Natl. Acad. Sci. USA, 102, 646(2005).
[73] B Sweeting, E Brown, M Q Khan, A Chakrabartty, E F Pai. PLoS One, 8(2013).
[74] D R Pérez, F F Damberger, K Wüthrich. J. Mol. Biol., 400, 121(2010).
[75] S Agarwal, K Döring, L A Gierusz, P Iyer, F M Lane, J F Graham, W Goldmann, T J T Pinheiro, A C Gill. Sci. Rep., 5(2015).
[76] K Kaneko, L Zulianello, M Scott, C M Cooper, A C Wallace, T L James, F E Cohen, S B Prusiner. Proc. Natl. Acad. Sci. USA, 94(1997).
[77] K J Knaus, M Morillas, W Swietnicki, M Malone, W K Surewicz, V C Yee. Nat. Struct. Biol., 8, 770(2001).
[78] T C Bjorndahl, G P Zhou, X Liu, R Perez-Pineiro, V Semenchenko, F Saleem, S Acharya, A Bujold, C A Sobsey, D S Wishart. Biochemistry, 50, 1162(2011).
[79] J Singh, H Kumar, A T Sabareesan, J B Udgaonkar. J. Am. Chem. Soc., 136(2014).
[80] J C Gower, G J S Ross. Appl. Stat., 18, 54(1969).
[81] J J Huang, X N Li, W L Liu, H Y Yuan, Y Gao, K Wang, B Tang, D W Pang, J Chen, Y Liang. J. Mol. Biol., 432, 828(2020).
[82] J Zuegg, J E Gready. Biochemistry, 38(1999).
[83] J Zhang. J. Theor. Biol., 269, 88(2011).
[84] Y Miao, S E Nichols, P M Gasper, V T Metzger, J A McCammon. Proc. Natl. Acad. Sci. USA, 110(2013).
[85] A del Sol, C J Tsai, B Ma, R Nussinov. Structure, 17, 1042(2009).
[86] P Csermely, R Palotai, R Nussinov. Nat. Prec., 1, 1(2010).
[87] P Csermely, T Korcsmáros, H J M Kiss, G London, R Nussinov. Pharmacol. Ther., 138, 333(2013).
[88] A Sethi, J Eargle, A A Black, Z Luthey-Schulten. Proc. Natl. Acad. Sci., 106, 6620(2009).
[89] J J Koehorst, J C J van Dam, E Saccenti, V A P Martins, M Suarez-Diez, P J Schaap. Bioinformatics, 34, 1401(2018).
[90] N Ahalawat, R K Murarka. J. Biomol. Struct. Dyn., 33, 2192(2015).
[91] J Yang, H Liu, X Liu, C Gu, R Luo, H F Chen. J. Chem. Inf. Model., 56, 1184(2016).
[92] S A Alcalá-Corona, T E Velázquez-Caldelas, J Espinal-Enríquez, E Hernández-Lemus. Front. Physiol., 7, 184(2016).
[93] C Guo, H X Zhou. Proc. Natl. Acad. Sci. USA, 113(2016).
[94] M Girvan, M E J Newman. Proc. Natl. Acad. Sci. USA, 99, 7821(2002).
[95]
[96] K Lindorff-Larsen, S Piana, K Palmo, P Maragakis, J L Klepeis, R O Dror, D E Shaw. Proteins Struct. Funct. Bioinforma., 78, 1950(2010).
[97] M J Abraham, T Murtola, R Schulz, S Páll, J C Smith, B Hess, E Lindah. SoftwareX, 1, 19(2015).
[98] T Darden, D York, L Pedersen. J. Chem. Phys., 98(1993).
[99] G Bussi, D Donadio, M Parrinello. J. Chem. Phys., 126(2007).
[100] M Parrinello, A Rahman. J. Appl. Phys., 52, 7182(1981).
[101] S Páll, B Hess. Comput. Phys. Commun., 184, 2641(2013).
[102] C Papadimitriou, M Sideri. J. Log. Program., 41, 129(1999).
[103] M E J Newman, M Girvan. Phys. Rev. E., 69(2004).
[104] W Humphrey, A Dalke, K Schulten. J. Mol. Graph., 14, 33(1996).
Get Citation
Copy Citation Text
Yiming Tang, Yifei Yao, Guanghong Wei. Structural and dynamical mechanisms of a naturally occurring variant of the human prion protein in preventing prion conversion[J]. Chinese Physics B, 2020, 29(10):
Received: Jun. 24, 2020
Accepted: --
Published Online: Apr. 21, 2021
The Author Email: Guanghong Wei (ghwei@fudan.edu.cn)